Exact Mass: 387.190645

Exact Mass Matches: 387.190645

Found 500 metabolites which its exact mass value is equals to given mass value 387.190645, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

4-Hydroxytamoxifen

4-[(1Z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol

C26H29NO2 (387.2198174)

4-Hydroxytamoxifen (Afimoxifene) is a metabolite of Tamoxifen. Afimoxifene (4-hydroxytamoxifen) is a selective estrogen receptor modulator which is the active metabolite of tamoxifen. Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel. (Wikipedia) D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent

Terazosin

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine

C19H25N5O4 (387.190645)

Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls. G - Genito urinary system and sex hormones > G04 - Urologicals > G04C - Drugs used in benign prostatic hypertrophy > G04CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents

nemonapride

C21H26ClN3O2 (387.17134460000005)

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Same as: D01468

3-Hydroxytamoxifen (Droloxifene)

3-[(1E)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol

C26H29NO2 (387.2198174)

3-Hydroxytamoxifen (Droloxifene) is only found in individuals that have used or taken Tamoxifen. 3-Hydroxytamoxifen (Droloxifene) is a metabolite of Tamoxifen. 3-hydroxytamoxifen (droloxifene) belongs to the family of Stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D020011 - Protective Agents > D000975 - Antioxidants D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Same as: D03911

alpha-Hydroxytamoxifen

(3E)-4-{4-[2-(dimethylamino)ethoxy]phenyl}-3,4-diphenylbut-3-en-2-ol

C26H29NO2 (387.2198174)

alpha-Hydroxytamoxifen is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)

Tamoxifen N-oxide

2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine oxide

C26H29NO2 (387.2198174)

Tamoxifen N-oxide is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)

Fingolimod phosphate ester, S-

2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol monodihydrogen phosphate ester

C19H34NO5P (387.2174484000001)

[1S-[1alpha,2alpha(Z),3alpha,4alpha]]-7-[3-[[2-[(Phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoicacid

C21H29N3O4 (387.21579540000005)

1-[(6-Chloro-2-methoxyacridin-9-yl)amino]-3-(diethylamino)propan-2-ol

1-[(6-chloro-2-methoxy-9,10-dihydroacridin-9-ylidene)amino]-3-(diethylamino)propan-2-ol

C21H26ClN3O2 (387.17134460000005)

Afimoxifene

4-(1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl)phenol

C26H29NO2 (387.2198174)

DV 7751a

6-{8-amino-6-azaspiro[3.4]octan-6-yl}-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid

C20H22FN3O4 (387.15942640000003)

(2S,3S)-Nemonapride

5-Chloro-2-methoxy-4-(methylamino)-N-(2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)benzamide

C21H26ClN3O2 (387.17134460000005)

Pcera-1

[1-(3-Methoxyphenyl)-1-(octanoylamino)propan-2-yl] dihydrogen phosphate

C18H30NO6P (387.18106500000005)

Tamoxifen-N-oxide

2-[4-(1,2-diphenylbut-1-en-1-yl)phenoxy]-N,N-dimethylethanamine oxide

C26H29NO2 (387.2198174)

trimebutine

2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoic acid

C22H29NO5 (387.20456240000004)

A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AA - Synthetic anticholinergics, esters with tertiary amino group D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D005765 - Gastrointestinal Agents Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects. Target: Opioid Receptor Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain [1]. The major product from drug metabolism of trimebutine in human beings is nor-trimebutine, which comes from removal of one of the methyl groups attached to nitrogen. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract [2, 3].

31F508a1

Bioxalomycin alpha1

C20H25N3O5 (387.179412)

Septenine

2-O-Acetyl-19-episeptentriosine

C22H29NO5 (387.20456240000004)

Isostemofoline

C22H29NO5 (387.20456240000004)

O-Methyltetradehydrotriphyophylline

(+)-O-Methyltetradehydrotriphyophylline

C25H25NO3 (387.18343400000003)

7beta-Hydroxycatuabine E

(+)-7beta-Hydroxycatuabine E

C20H25N3O5 (387.179412)

Androbiphenyline

C21H25NO6 (387.168179)

16-Oxohasubanonine

C21H25NO6 (387.168179)

13-O-Acetylvakhmatine

C22H29NO5 (387.20456240000004)

1-hydroxy-2,3,9,10-tetramethoxyaporphine N-oxide

C21H25NO6 (387.168179)

Merenderine N-oxide

C21H25NO6 (387.168179)

Majusidine A

C22H29NO5 (387.20456240000004)

Marinacarboline A

C23H21N3O3 (387.1582836)

A natural product found in Marinactinospora thermotolerans.

EAM-2201

C26H26FNO (387.1998318)

Oprea1_090564

C19H25N5O4 (387.190645)

2-(1-(cyclohexylmethyl)-1H-indazole-3-carboxamido)-3-methylsuccinicacid

C20H25N3O5 (387.179412)

MAB-CHMINACA metabolite M3

C21H29N3O4 (387.21579540000005)

Oprea1_323579

C22H26ClNO3 (387.16011160000005)

trimebutine

C22H29NO5 (387.20456240000004)

MMV688547

C21H21N7O (387.1807496)

MMV687172

C23H25N5O (387.2059)

TCMDC-125412

C22H21N5O2 (387.1695166)

MMV688407

C21H21N7O (387.1807496)

MMV688474

C21H21N7O (387.1807496)

Cyhexatin

C18H35OSn (387.170975)

D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals

Saxoguattine

C21H25NO6 (387.168179)

guanacastepene H

C22H29NO5 (387.20456240000004)

SCHEMBL17866949

C21H25NO6 (387.168179)

Cystodytin F

C23H21N3O3 (387.1582836)

An alkaloid that is an enamide obtained by the formal condensation of 3-methylbut-2-enoic acid with 6-(2-amino-1-methoxyethyl)-4H-pyrido[2,3,4-kl]acridin-4-one. It is isolated from the Okinawan marine tunicate Cystodytes dellechiajei and exhibits cytotoxicity against human epidermoid carcinoma KB cells.